Leukaemia cell drug resistance and prognostic factors in AML

European Journal of Haematology

Volumn 63, Issue 4, 1999, Pages 219-224

  Nørgaard, Jan Maxwell ^a,b   Olesen, Gitte ^a   Kristensen, Jørgen S ^a   Pedersen, Bent ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Aarhus Amtsygehus   (Denmark)

Author keywords

AML; Cytogenetic abnormalities; Drug resistance; Prognostic factors

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CYTOGENETICS; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIDRUG RESISTANCE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 1842869681     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01881.x     Document Type: Article

References (29)

1. 1. REES JKH, GRAY R, SWIRSKY D, et al. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986;ii:1236-41.
2. 2. BELL R, ROHATINER AZS, SLEVIN ML, et al. Short-term treatment for acute myelogenous leukaemia. Br Med J 1982;284:1221-4.
3. 3. LEITH CP, KOPECKY KJ, GODWIN J, et al. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study. Blood 1997;89:3323-9.
4. 4. HOYLE CF, DE BASTOS M, WHEATLEY K, et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from MRC's 9th AML trial. Br J Haematol 1989;72:45-53.
5. 5. GAJEWSKI JL, HO WG, NIMER SD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989;7:1637-45.
6. 6. SCHIFFER CA, LEE EJ, TOMIYASU T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989;73:263-70.
7. 7. KLUMPER E, OSSENKOPPELE GJ, PIETERS R, et al. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996;93:903-10.
8. 8. TAUB JW, MATHERLY LH, STOUT ML, et al. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996;87:3395-403.
9. 9. TOSI P, VISANI G, OTTAVIANI E, et al. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro.. Eur J Haematol 1998;60:161-5.
10. 10. RAVINDRANATH Y, ABELLA E, KRISCHER JP, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992;80:2210-4.
11. 11. HONGO T, YAJIMA S, SAKURAI M, et al. In vitro sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 1997;89:2959-65.
12. 12. KASPERS GJL, SMETS LA, PIETERS R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study. Blood 1995;85:751-6.
13. 13. NØRGAARD JM, JENSEN PD, BENDIX K, et al. Relevance of in vitro leukaemia cell survival to short-and long term clinical outcome in AML. Leuk Lymphoma 1999;93: 32:327-37.
14. 14. NØRGAARD JM, LANGKJER ST, PALSHOF T, et al. Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Br J Haematol 1996;93:888-97.
15. 15. KRISTENSEN JS, HOKLAND P. Monoclonal antibodies in myeloid diseases: Prognostic use in acute myeloid leukaemia. Leuk Res 1991;15:693-700.
16. 16. BENNETT JM, CATOWSKY D, DANIEL MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. Ann Int Med 1985;103:620-5.
17. 17. BENNETT JM, CATOWSKY D, DANIEL MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991;78:325-9.
18. 18. ELLISON RR, HOLLAND JF, WEIL M, et al. Arabinosyl cytosine: useful agent in the treatment of acute leukemia in adults. Blood 1968;32:507-23.
19. 19. NØRGAARD JM, BUKH A, LANGKJER ST, et al. MDR1 gene expression and drug resistance of AML cells. Br J Haematol 1998;100:534-40.
20. 20. PEDERSEN B, KERNDRUP G. Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes. Cancer Genet Cytogenet 1986;23:61-75.
21. 21. DASTUGUE N, PAYEN C, LAFAGE POCHITALOFF M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995;9:1491-8.
22. 22. IWASAKI H, HUANG P, KEATING MJ, et al. Differential incorporation of Ara-C, Gemcitabine, and Fludarabine into replicating and repairing DNA in proliferating human leukemia cell. Blood 1997;90:270-8.
23. 23. NØRGAARD JM, LANGKJER ST, ELLEGAARD J, et al. Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs. Leuk Res 1993;17:689-94.
24. 24. LILIEMARK JO, PLUNKETT W. Regulation of 1-b-D-arabinofuranosylcytosine 5′-triphosphate accumulation in human leukemia cells by deoxycytidine 5′-triphosphate. Cancer Res 1986;46:1079-83.
25. 25. LEONI F, CIOLLI S, GIULIANI G, et al. Attenuated-dose idarubicin in acute myeloid leukaemia of the elderly: pharmacokinetic study and clinical results. Br J Haematol 1995;90:169-74.
26. 26. PEDERSEN-BJERGAARD J, PEDERSEN M, ROULSTON D, et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86:3542-52.
27. 27. FRICHE E, SKOVSGAARD T, NISSEN NI. Anthracycline resistance. Acta Oncol 1989;28:877-81.
28. 28. BAHLLA K, HUANG Y, TANG C, et al. Characterization of a human myeloid leukemia cell line resistant to taxol. Leukemia 1994;8:465-75.
29. 29. GOSLAND MP, GILLESPIE MN, TSUBOI CP, et al. Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine. Cancer Chemother Pharmacol 1996;37:593-600.